Results 281 to 290 of about 21,646,956 (389)
NOTCH2NLC Repeat Expansions in Parkinsonian Disorders: Clinical and Neuroimaging Characteristics
ABSTRACT Objective Neuronal intranuclear inclusion disease (NIID) is a neurodegenerative disorder caused by NOTCH2NLC GGC repeat expansions, with heterogeneous clinical manifestations, including parkinsonism. Recent studies have identified NOTCH2NLC repeat expansions in patients with Parkinson's disease (PD) and atypical parkinsonism (aPM), suggesting ...
Han‐Lin Chiang+7 more
wiley +1 more source
Assessing patients' knowledge immediately after obtaining the antibacterial drug azithromycin: a community pharmacy-based cross-sectional study. [PDF]
Mohamed AS, Refaei HMA, Rofaeil RR.
europepmc +1 more source
ABSTRACT Objectives Repetitive transcranial magnetic stimulation (rTMS) is a non‐invasive brain stimulation strategy with a demonstrated potential to reinforce the residual pathways after a spinal cord injury (SCI). A preclinically tested high‐frequency (15 Hz) rTMS (15 Hz rTMS) protocol was shown to induce corticospinal tract axon regeneration growth ...
Nabila Brihmat+8 more
wiley +1 more source
Applying health belief model among mothers of children with thalassemia. [PDF]
Khawwas HSM+3 more
europepmc +1 more source
The role of traditional ecological knowledge and ecosystem quality in managing ecosystem services. [PDF]
Khosravi Mashizi A, Escobedo F.
europepmc +1 more source
ABSTRACT Background Stroke is a leading cause of long‐term disability in adults, with upper limb hemiparesis being a common impairment. Traditional training is mostly aimed at paralyzed limbs, but the effect of bilateral training is still unclear.
Fangfang Qian+7 more
wiley +1 more source
Proof of concept studies in mental health systems research: strategy and steps. [PDF]
Salvador-Carulla L+3 more
europepmc +1 more source
Practice Recommendations for Genetic Testing of Ataxias
ABSTRACT Objective Over the past decade, significant advances in genetic testing for ataxia have improved diagnostic accuracy, informed clinical trial eligibility, guided treatment decisions, and enabled cascade testing of at‐risk relatives. While guidance exists for other neurogenetic conditions, there are no standardized guidelines on genetic ...
Sharan R. Srinivasan+7 more
wiley +1 more source